AbCellera Biologics Inc vs Coinbase Global, Inc. — how do they compare? AbCellera Biologics Inc trades at $9.23 (market cap $2.99B), while Coinbase Global, Inc. trades at $150.17 (market cap $39.20B). The key difference: Coinbase Global, Inc. is far larger — about 13.1× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Coinbase Global, Inc. nearer its low. Which is the better fit depends on your goals.
| ABCL | COIN | |
|---|---|---|
Market Cap | $2.99B | $39.20B |
Sector | Health | Technology |
52-Week High | $9.76 | $387.27 |
52-Week Low | $2.78 | $141.09 |
Enterprise Value | $2.58B | $36.85B |
Trailing returns across standard periods
Latest headlines on both assets
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →